Beyond the Stain: BAP1 ‐Inactivated Melanocytic Tumors With Retained BAP1 Nuclear Expression due to Missense Mutations in the Catalytic Domain
Journal of Cutaneous Pathology · 2026-06 · 53 (6) · 511-517
DOI: 10.1111/cup.70086 ↗At a glance
Fallbericht in Journal of Cutaneous Pathology, published online on 2026-03-11. Written by Silvija Milanovic and 13 co-authors. Institution: University of Florida, College of Medicine, Gainesville, Florida, USA. Major MEDLINE topics: Cell Nucleus, Melanoma, Mutation, Missense, Skin Neoplasms. 19 references.
Abstract (original language)
BAP1 ‐inactivated melanocytic tumors (BIMTs) demonstrate loss of BAP1 nuclear expression by immunohistochemistry (IHC), which serves as a key diagnostic marker. Here, we present four cases of BIMTs with retained BAP1 nuclear expression. All cases demonstrated dual cytomorphology, low mitotic activity, and either absence of PRAME expression or only weak focal expression. Three cases demonstrated BAP1 p.H169Y missense mutations alongside BRAF V600E mutations. In one case, a BAP1 p.G185R missense mutation and a BRAF V600_S602delinsDT mutation were identified. Both BAP1 missense variants were located in the functional ubiquitin carboxyl hydrolase (UCH) domain at the N‐terminus. Although most BAP1 mutations are missense, the majority lead to loss of nuclear expression by IHC due to misfolding or impaired nuclear localization. Therefore, IHC directed against the C‐terminus of BAP1 protein remains a sensitive diagnostic tool. In contrast, the p.H169Y and p.G185R variants appear to uniquely preserve both protein folding and nuclear localization, allowing retained nuclear expression despite functional inactivation. Therefore, in tumors with morphologic features suggestive of BIMT, retained BAP1 nuclear expression should not preclude diagnosis or additional molecular testing to confirm BAP1 inactivation.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- University of Florida, College of Medicine, Gainesville, Florida, USA.
- Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida, USA.
- Department of Dermatology, University of Washington, Seattle, Washington, USA.
- School of Medicine, University of Washington, Seattle, Washington, USA.
- Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
ORCID profiles: Lindsay Gunnell, Oliver Chang, Yvonne Chiu, Kiran Motaparthi
Cite
APA
Milanovic, S., Sun, C., Gunnell, L., Wilk, V., Shinohara, M. M., Chang, O., Admassu, N., Chiu, Y., Wanat, K. A., Young, K. E., Xu, Y., Flaman, A. N., Nohr, E., & Motaparthi, K. (2026). Beyond the Stain: BAP1 ‐Inactivated Melanocytic Tumors With Retained BAP1 Nuclear Expression due to Missense Mutations in the Catalytic Domain. Journal of Cutaneous Pathology, 53(6), 511-517. https://doi.org/10.1111/cup.70086
Vancouver
Milanovic S, Sun C, Gunnell L, Wilk V, Shinohara MM, Chang O, et al. Beyond the Stain: BAP1 ‐Inactivated Melanocytic Tumors With Retained BAP1 Nuclear Expression due to Missense Mutations in the Catalytic Domain. Journal of Cutaneous Pathology. 2026;53(6):511-517. doi:10.1111/cup.70086
BibTeX
@article{Milanovic2026,
author = {Milanovic, Silvija and Sun, Christina and Gunnell, Lindsay and Wilk, Victoria and Shinohara, Michi M and Chang, Oliver and Admassu, Natnaelle and Chiu, Yvonne and Wanat, Karolyn A and Young, Kara E and Xu, Yitong and Flaman, Ashley N and Nohr, Erik and Motaparthi, Kiran},
title = {Beyond the Stain: BAP1 ‐Inactivated Melanocytic Tumors With Retained BAP1 Nuclear Expression due to Missense Mutations in the Catalytic Domain},
journal = {Journal of Cutaneous Pathology},
year = {2026},
volume = {53},
number = {6},
pages = {511--517},
doi = {10.1111/cup.70086}
}
EUVIMED